Executive leadership at EXOZYMES.
Board of directors at EXOZYMES.
Research analysts covering EXOZYMES.
Recent press releases and 8-K filings for EXOZ.
eXoZymes Reports Strong Production Metrics for Initial NCT Pilot Run
EXOZ
Product Launch
New Projects/Investments
- eXoZymes Inc. announced successful results from its initial 100-liter pilot production run of N-trans-caffeoyltyramine (NCT), achieving approximately 99% reaction conversion, 90% isolated yield, and producing 535 grams of NCT at 99.6% pharma-grade purity.
- The pilot production was executed by an external partner, Cayman Chemical, demonstrating the transferability and operational robustness of eXoZymes' biomanufacturing process, with reaction performance observed to improve at increased operating scale.
- High-purity NCT is now available for formulation development with commercial partners, and eXoZymes expects 2026 to focus on establishing a commercial NCT supply chain and forming strategic partnerships.
2 days ago
eXoZymes Announces 100-Fold Scale-Up of NCT Production
EXOZ
New Projects/Investments
- eXoZymes Inc. announced the successful achievement of a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production process.
- This process utilizes the company's proprietary exozyme-based, cell-free biomanufacturing platform.
- The scale-up demonstrated a conversion level of over 99% from feedstock to product.
- The batch production was executed under partner-operated conditions by Cayman Chemical.
- Additional technical details regarding the isolation process and data analysis are expected in early 2026.
Dec 12, 2025, 12:43 AM
EXOZ Reports Q3 2025 Financials, Advances Key Bio-Solutions, and Announces Leadership Appointments
EXOZ
Earnings
New Projects/Investments
Management Change
- EXOZ reported $5.1 million in cash and cash equivalents as of September 2025, providing liquidity into Q2 2026, with a Q3 2025 net loss of $2.29 million and total operating expenses of $2.52 million.
- The company is advancing three bio-solutions: NCT, targeting metabolic performance with a multi-billion dollar market potential ; non-intoxicating cannabinoids, benefiting from a new law and also having billion-dollar market potential ; and Sandeline, supported by a $3 million grant from the National Science Foundation.
- EXOZ is pursuing a joint venture for cannabinoids but is delaying NCT partnerships to maximize shareholder value, while maintaining a capital-light strategy and exploring non-dilutive funding.
- Amy Lunzer was promoted to Chief of Staff, and co-founder Tyler Korman was appointed Chief Scientific Officer.
Nov 13, 2025, 10:00 PM
Quarterly earnings call transcripts for EXOZYMES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more